-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Primary liver cancer (PLC) mainly includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and mixed HCC-ICC, among which HCC accounts for about 90% of all cases.
In 2018, there were approximately 841,000 new cases of PLC worldwide, and approximately 782,000 died of liver cancer.
The latest clinical data indicate that immune checkpoint inhibitors combined with anti- angiogenesis agents are a reasonable strategy for the treatment of a variety of malignant tumors .
Immune checkpoint inhibitors in combination with anti angiogenesis generator is reasonable strategy to treat a variety of malignant tumors of immune vessels
This study is a multi-cohort phase Ib/II trial to evaluate the effect of human PD-1 monoclonal antibody Camrelizumab combined with apatinib in the treatment of advanced PLC.
To evaluate the effect of human PD-1 monoclonal antibody Camrelizumab combined with apatinib in the treatment of advanced PLC.
PLC patients after systemic treatment were given Camrelizumab (3 mg/kg, 1/2 week) and apatinib (125, 250, 375 or 500 mg, 1/ Days) treatment.
Research Process
Research ProcessFrom April 2017 to July 2019, a total of 28 patients (21 cases of HCC and 7 cases of ICC) received Camrelizumab + apatinib treatment.
Treatment interruption and dose reduction in the 375 mg group
Treatment interruption and dose reduction in the 375 mg groupTwo dose-limiting toxicities were reported in the 500 mg group (both grade 3 diarrhea).
Two dose-limiting toxicities were reported in the 500 mg group (both grade 3 diarrhea).
Adverse events
Adverse eventsAmong 28 patients with liver cancer, 26 had treatment-related adverse events ≥ grade 3, of which the most common was hypertension (9/28).
treatment effect
treatment effectThe objective effective rate was 10.
The objective effective rate was 10.
The toxicity of Camrelizumab combined with apatinib in the treatment of advanced PLC is controllable and has good anti-tumor activity.
Original source:
Mei Kuimin,Qin Shukui,Chen Zhendong et al.
Leave a message here
